Association of Hiccup and SARS-CoV-2 Infection with the Administration of Dexamethasone: A Case Report

Abstract

Introduction: Among the less common symptoms associated with the SARS-CoV-2 infection the attention is drawn by a persistent hiccup that was recently quoted in the literature. Case report: We present the case of a 46-year-old Caucasian male patient hospitalized in the Infectious Diseases Clinic of the Academic Emergency Hospital Sibiu, Romania with laboratory confirmation of SARS-CoV-2 infection with a positive result of real-time reverse transcriptase–polymerase chain reaction (RT-PCR) assay from nasopharyngeal swabs, that during the disease course developed persistent hiccup associated with the administration of cortisone therapy, dexamethasone. A decision to stop the treatment with cortisone preparations was made, with the disappearance of the hiccup after 36 h. Conclusions: From our experience, other cases of SARS-CoV-2 infection that we managed during these months of the pandemic, with mild or severe forms of the disease, showed hiccup under treatment with dexamethasone, an event also described in other medical conditions under the same treatment and improved at its cessation or when replaced by methylprednisolone.

Introduction

SARS-CoV-2 infection was initially associated with standard symptomatology—fever, dyspnea, dry cough, and in dynamics with digestive manifestations—nausea, diarrhea, vomiting, anosmia, ageusia, neurological or cardiovascular manifestations. Subsequently, there were cases of COVID-19 that associated at the beginning or during the disease course micturition syncope [1,2,3], viral exanthema [4–7], psychiatric and thromboembolic manifestations, etc. Among the less common symptoms, the attention is drawn by the persistent hiccup recently quoted in the literature [8]. We present the case of a COVID-19 patient hospitalized in the Infectious Diseases Clinic of the Academic Emergency Hospital Sibiu, Romania with laboratory confirmation of SARS-CoV-2 infection with a positive result of real-time reverse transcriptase–polymerase chain reaction (RT-PCR) assay from nasopharyngeal swabs, that associated during the disease course persistent hiccup associated with the administration of cortisone therapy, dexamethasone.

Case report

We present the case of a 46-year-old Caucasian male, without comorbidities, non-smoker, who presented for admission into the Infectious Diseases Clinic of the Academic Emergency Hospital Sibiu, Romania 8 days after the onset of abdominal pain, accompanied after one day by dysphonia, headache, chills, low-grade fever, dry cough, insomnia, and inappetence. The patient was confirmed with SARS-CoV-2 infection by RT-PCR assay from nasopharyngeal swabs on the third day of disease onset. He was under treatment, self-medication, before his admission into the hospital, from the fourth day of the disease evolution, with dexamethasone 10 mg 2 times per day orally, ivermectin 12 mg 1 time per day orally, enoxaparin 60 mg in 0.6 mL, 1 single dose syringe/day for subcutaneous administration, pantoprazole 40 mg/day orally, and paracetamol 500 mg orally as needed. The next day of treatment (day five since disease onset), the following changes were noticed by the patient: rebel hiccups, accentuated at night, associated with insomnia, and fatigue. During the next 3 days (day five to day eight since disease onset), the patient presented a fever of 38 °C, dry cough, inappetence, the hiccup was accentuated and was not responsive to the administration of metoclopramide. The admission of the patient into the hospital was decided, laboratory changes suggesting an inflammatory syndrome. The pulmonary computerized tomography (CT) scan performed on day eight since disease onset revealed the following pathological changes: multiple areas of ground glass aspect, disseminated bilaterally, both peripherally, and also in upper lobes; alveolar consolidation areas that were occupying 5% of the right upper and left upper lobe and 25% of the left lower lobe respectively (Figure 1 and Figure 2).

At the time of admission on physical examination, the following changes were noticed: 37.5 °C fever, sweaty skin, dry cough, bilateral pulmonary crackles on auscultation, peripheral oxygen saturation 96% in ambient air and without the need of oxygen supplementation, heart rate of 104 beats per minute, and blood pressure 125 over 80 mmHg. Treatment with remdesivir was initiated consisting of a loading dose of 200 mg intravenously on the first day of admission, followed by 100 mg daily for the following 5 days, remdesivir being prescribed based on the available national guideline. Dexamethasone was replaced after 2 days from admission with methylprednisolone 250 mg/day intravenously for 3 days, under which the patient continued to show the same manifestations (accentuated nocturnal hiccup and fatigue) with a discrete improvement under treatment with intravenous metoclopramide 10 mg 3 times per day, intravenous ondansetron 4 mg 2 times per day, and intravenous drotaverine hydrochloride 40 mg 3 times per day.

A decision to stop the administration of cortisone drugs was made, with the disappearance of the hiccup after 36 h. The patient was discharged after 7 days, afebrile, without clinical respiratory or digestive manifestations. The most important laboratory studies are presented in Table 1.

Discussion

Hiccup represents an involuntary way of paroxysmal movements in the inspiration action of the chest, associated with the contraction of the diaphragm and of the adjacent muscles and with the closure of the epiglottis [9].

The causes of the hiccup, as a manifestation of the phrenic nerve irritation, may be associated with subphrenic hepatic abscess, pancreatitis, renal insufficiency, influenza, tuberculosis, alcohol consumption, gastric distension, reflux esophagitis [10], or with esophageal adenocarcinoma [11], gastroduodenitis, and enteritis. Other cited causes associated with hiccup are: myocardial infarction [12,13,14], pulmonary embolism [15], cerebral tumors, meningitis, prostatic neoplasm [11], idiopathic, and more recently, SARS-CoV-2 infection [8,16,17].

Few cases with hiccup associated with the SARS-CoV-2 infection have been reported to this point in the literature. The first case, described by Prince et al., is the case of a 62-year-old male known with diabetes mellitus and cardiovascular disease, that presented hiccup for 7 days and weight loss. Biologically he presented leukopenia, thrombocytopenia, hyponatremia, and hypochloremia [8].

The second case [17] was the case of a 48-year-old male, known with essential high blood pressure, hospitalized on the seventh day of hiccup, with pulmonary changes of bilateral basal subpleural opacity and crazy paving pattern. Among the laboratory examinations performed in this case, C-reactive protein was increased (51 mg/L), ferritin 2600 ng/mL, LDH 856 U/L. Under treatment with baclofen, the patient continued to present hiccups for another 7 days.

The third case is described by Dorgalaleh, also a 52-year-old male, known with diabetes mellitus and congenital V-factor deficit, [18] with a persistent hiccup, which the author associated in favor of epistaxis.

The case presented in this article is the case of a male patient without a past medical history, in which the hiccup occurred during treatment with dexamethasone and methylprednisolone, and disappeared when this treatment was stopped.

From our experience, other cases of SARS-CoV-2 infection that we have been tracking during these months of the pandemic, with mild or severe forms of the disease, showed hiccup under dexamethasone treatment, an event also described in other medical conditions under the same treatment [19,20] and improved at its cessation or when replaced by methylprednisolone.

Conclusions

All the cases described, with hiccup and SARS-CoV-2 infection presented so far have occurred in male patients, the case presented by us being the only one associated with the administration of dexamethasone to a patient without any comorbidity. Discontinuation of dexamethasone, and the use of metoclopramide, ondansetron or haloperidol may be beneficial in such disease conditions.